Literature DB >> 7959262

Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy.

R L Coleman1, E D Keeney, R S Freedman, T W Burke, P J Eifel, F N Rutledge.   

Abstract

Patients with small recurrent cervical carcinomas following radiation therapy may be salvaged with radical hysterectomy rather than exenteration. Between 1953 and 1993, 50 patients underwent radical hysterectomy for persistent (n = 18) or recurrent (n = 32) cervical cancer after primary radiotherapy. The mean age of the cohort was 44 years (range, 23-70). Histologic types were squamous in 46, adenocarcinoma in 3, and adenosquamous in 1. Of 37 patients with staged disease, 24 had stage IB/IIA, 7 had stage IIB, 2 had stage IIIA, and 2 had stage IIIB. Combination radiotherapy, consisting of 40-45 Gy external-beam radiation plus brachytherapy (mean 6980 mg/hr), was performed in 32 patients (64%). In the 32 patients with recurrent lesions, the median interval from definitive radiotherapy to radical hysterectomy was 16 months (4-301), with 19 of these patients (60%) presenting within the first 24 months. Patients with persistent carcinomas underwent radical hysterectomy after a median observation interval of 2 months (1-4). A class II or III radical hysterectomy was performed in 39 (78%) cases. Pelvic and para-aortic lymph node samplings were performed in 39 patients (78%), including 33 (66%) who underwent complete pelvic lymphadenectomy. Among those sampled, 5 (13%) had metastatic nodal disease. All 5 patients died of disease at a median 13 months after surgery. Severe postoperative complications occurred in 21 patients (42%). The most common site of injury was the urinary tract, with 14 patients (28%) developing vesicovaginal or rectovaginal fistulae, 11 (22%) developing ureteral injuries, and 10 (20%) developing severe long-term bladder dysfunction. There was one postoperative death from sepsis among the entire population. Patients with abnormal preoperative intravenous pyelograms (P < 0.05), patients with recurrent presurgical lesions (P < 0.05), and patients with postoperative pelvic cellulitis (P < 0.01) were more likely to develop fistulae. The 5- and 10-year actuarial survival rates for all cases was 72 and 60%, respectively. Tumor size at radical hysterectomy was significantly associated with survival. Five-year actuarial survival in 12 of 44 patients (27%) with identifiable lesion diameters less than 2 cm was 90% compared with 64% in patients with larger lesions (P < 0.01). Prolonged disease-free survival occurred in 26 of 50 patients (52%) who had known disease status at follow-up, whereas recurrence after radical hysterectomy was seen in 24 patients (48%).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 7959262     DOI: 10.1006/gyno.1994.1242

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

1.  Hysterectomy for Recurrent/Residual Cervical Cancer Following Definitive Radiotherapy.

Authors:  Tadaharu Nakasone; Yusuke Taira; Yuko Shimoji; Yoshihisa Arakaki; Tomoko Nakamoto; Takuma Ooyama; Wataru Kudaka; Itomi Kaneshima; Kumiko Nishihira; Keiko Mekaru; Yoichi Aoki
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Adjuvant hysterectomy after radiochemotherapy for locally advanced cervical cancer.

Authors:  Peter Hass; Holm Eggemann; Serban Dan Costa; Atanas Ignatov
Journal:  Strahlenther Onkol       Date:  2017-06-28       Impact factor: 3.621

3.  The efficacy of surgical treatment of recurrent or persistent cervical cancer that develops in a previously irradiated field: a monoinstitutional experience.

Authors:  Seiji Mabuchi; Yuri Matsumoto; Naoko Komura; Masaaki Sawada; Mie Tanaka; Eriko Yokoi; Katsumi Kozasa; Akihiko Yoshimura; Hiromasa Kuroda; Tadashi Kimura
Journal:  Int J Clin Oncol       Date:  2017-05-27       Impact factor: 3.402

4.  Treatment options in recurrent cervical cancer (Review).

Authors:  Angiolo Gadducci; Roberta Tana; Stefania Cosio; Luca Cionini
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

5.  Optimal cutoff level of serum squamous cell carcinoma antigen to detect recurrent cervical squamous cell carcinoma during post-treatment surveillance.

Authors:  Jinju Oh; Jin Young Bae
Journal:  Obstet Gynecol Sci       Date:  2018-04-23

6.  Pelvic Exenteration for Recurrent and Persistent Cervical Cancer.

Authors:  Lei Li; Shui-Qing Ma; Xian-Jie Tan; Sen Zhong; Ming Wu
Journal:  Chin Med J (Engl)       Date:  2018-07-05       Impact factor: 2.628

Review 7.  Image-Guided Brachytherapy for Salvage Reirradiation: A Systematic Review.

Authors:  Sophie Bockel; Sophie Espenel; Roger Sun; Isabelle Dumas; Sébastien Gouy; Philippe Morice; Cyrus Chargari
Journal:  Cancers (Basel)       Date:  2021-03-11       Impact factor: 6.639

8.  Significance of the Number and the Location of Metastatic Lymph Nodes in Locally Recurrent or Persistent Cervical Cancer Patients Treated with Salvage Hysterectomy plus Lymphadenectomy.

Authors:  Seiji Mabuchi; Naoko Komura; Michiko Kodama; Michihide Maeda; Yuri Matsumoto; Shoji Kamiura
Journal:  Curr Oncol       Date:  2022-07-11       Impact factor: 3.109

9.  Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy.

Authors:  T Ota; N Takeshima; T Tabata; K Hasumi; K Takizawa
Journal:  Br J Cancer       Date:  2008-10-21       Impact factor: 7.640

10.  Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with locally advanced cervical cancer treated with radiation or chemoradiation.

Authors:  Jinju Oh; Hyun Joo Lee; Tae Sung Lee; Ju Hyun Kim; Suk Bong Koh; Youn Seok Choi
Journal:  Obstet Gynecol Sci       Date:  2016-07-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.